Interestingly, despite reduced angiogenesis, VEGFR2 inhibition in combination with talazoparib only modestly reduced tumor growth in the Brca1-def and Bard1-def models (Figs. 2J,K; EV2D), suggesting that other mechanisms are important for driving in-vivo PARPi resistance. Here, KDR is linked to neoplasm.